Represent CyVek, Inc., which is engaged in the development of a novel, multiplex platform system for immunoassays for measuring analytes in biological samples, particularly to serve the market needs of biomarker validation throughout the life sciences and clinical diagnostics fields. We provide CyVek with general counseling and advice on corporate governance, finance, equity compensation, tax and contracts, including research and development agreements with other life science companies and universities. Most recently, we represented CyVek in its $3 million Series C Preferred Stock financing, in which all of its existing investors, including Connecticut Innovations, participated.